Plain-English translation of NCT05101213 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach to treating viral infections in cancer patients whose immune systems are weakened. Researchers have genetically engineered special immune cells called CTLs (cytotoxic T-lymphocytes) to be more effective at fighting viruses. The study will assess whether these engineered cells are safe and whether they can help patients recover from serious viral infections.
Cancer patients—especially those who have received stem cell transplants—often have weakened immune systems that cannot fight off dangerous viral infections on their own. Current treatments don't always work well, so this trial is exploring whether these specially engineered immune cells could offer a new way to help these vulnerable patients.
You likely qualify if…
You likely don't qualify if…
You will receive the engineered immune cells as an intravenous infusion over 30 minutes. Depending on how well you respond, you may receive up to 8 additional infusions spaced at least 2 weeks apart. After treatment ends, you will be followed up with yearly visits for 15 years to monitor your health, how long the cells persist in your body, and how well you're doing overall.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States